Equitable access to essential medicines is crucial to improve population health and support economic growth. A diverse range of access strategies have been implemented to target barriers across the different dimensions of access. This thesis contributes to the evidence on access to medicines strategies, focusing largely on international coordination and policy. First, I conduct a scoping review to identify strategies instigated by different stakeholders to improve access across a broad range of therapeutic areas and country contexts (Chapter 2). The remainder of the thesis seeks to address some of the literature gaps identified in this review. I explore inequalities and inequities in WHO essential medicines compared with need (Chapter 3). I...
To date, much of the academic and policy literature has focused on the impact of intellectual proper...
Access to essential medicines is a core element of the effective health systems that are required to...
Access to new cancer medicines, particularly their coverage and affordability, is a matter of great ...
Background: Access to essential medicines for the world's poor and vulnerable has made little progre...
This chapter illustrates how human rights principles can help governments, even those with the most ...
Gorik Ooms and Johanna Hanefeld argue that low and middle income countries could increase access to ...
This thesis investigates four cross-cutting controversies in access to medicines – aspects of pharma...
It is a vast understatement to say that the problem of access to medicines in developing countries i...
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in ...
Background Voluntary licences are increasingly being used to expand access to patented essential med...
Background: Budgetary constraints and the rising cost of new innovative medicines are the key challe...
Although essentially not all therapies need drug intervention, drugs is still an important component...
and concluding remarks Expanding access to essential medicines requires attention to a diverse set o...
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in ...
BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medic...
To date, much of the academic and policy literature has focused on the impact of intellectual proper...
Access to essential medicines is a core element of the effective health systems that are required to...
Access to new cancer medicines, particularly their coverage and affordability, is a matter of great ...
Background: Access to essential medicines for the world's poor and vulnerable has made little progre...
This chapter illustrates how human rights principles can help governments, even those with the most ...
Gorik Ooms and Johanna Hanefeld argue that low and middle income countries could increase access to ...
This thesis investigates four cross-cutting controversies in access to medicines – aspects of pharma...
It is a vast understatement to say that the problem of access to medicines in developing countries i...
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in ...
Background Voluntary licences are increasingly being used to expand access to patented essential med...
Background: Budgetary constraints and the rising cost of new innovative medicines are the key challe...
Although essentially not all therapies need drug intervention, drugs is still an important component...
and concluding remarks Expanding access to essential medicines requires attention to a diverse set o...
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in ...
BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medic...
To date, much of the academic and policy literature has focused on the impact of intellectual proper...
Access to essential medicines is a core element of the effective health systems that are required to...
Access to new cancer medicines, particularly their coverage and affordability, is a matter of great ...